The approval is a vindication for a shot seen as essential for mass immunisations in the developing world as well as in Britain, but does not eliminate questions about trial data that make it unlikely to be approved so rapidly in the European Union or the United States.
 |
| AstraZeneca/Oxford COVID-19 vaccine |
“The NHS (National Health Service) will be able to deliver these shots into people’s arms at the speed at which it can be manufactured,” Health Secretary Matt Hancock told Sky News.
“I am also now, with this approval this morning, highly confident that we can get enough vulnerable people vaccinated by the spring that we can now see our route out of this pandemic.”
Johnson called the approval a “triumph for British science”.
Hancock said hundreds of thousands of doses would be available to administer next week in Britain, which is already rolling out a vaccine developed by Pfizer of the United States and BioNTech of Germany.
The Oxford vaccine has been found in trials to be less effective than the Pfizer/BioNTech shot but, crucially for countries with more basic health infrastructure, can be stored and transported under normal refrigeration, rather than supercooled to -70 degrees Celsius (-94 Fahrenheit).
INDIA INTERESTED
India is keen to start administering the new shot next month; Serum Institute of India (SII), the world’s biggest producer of vaccines, has already made about 50 million doses. Chile is also interested.Britain has set itself apart from other Western countries with its fast-track approach to vaccinations, having green-lighted the Pfizer/BioNTech vaccine weeks before the EU’s European Medicines Authority (EMA) did so.
A UK government advisory body on Wednesday recommended a change of course by giving as many people as possible a first dose of coronavirus vaccine right away, rather than giving the second, booster shot within the shortest period of time.
Uncertainty has swirled over the most effective dosing pattern for the AstraZeneca/Oxford vaccine since it released data last month showing a 90% success rate for a half-dose followed by a full dose, but only 62% - still usually more than enough for regulators - for two full doses.
The more successful outcome emerged, by accident, in a much smaller number of participants, all under 55, and AstraZeneca is carrying out more tests to see if that rate holds up in a bigger set of volunteers.
